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direct interviews and auditorium/e-mail/internet/postal surveys among pharma-
cists (28/27 questions for public pharmacies (PP)/hospital pharmacies (HP) respec-
tively) and consumers (13 questions). RESULTS: The survey was conducted be-
tween May and October 2011 among PP (N958) and HP (N91). 38.1 % PP and 59.3%
HP confirmed that the level of their knowledge of PT is definitely unsatisfactory and
requires substantial broadening. The majority of pharmacists believe medicines
from PT to be as safe as other medicines (83.4 %/74.2% PP/HP respectively). Almost
40% of pharmacists agree that the introduction of PT medicines has increased
competitive pressure and contributed to a decrease in the prices of medicines
registered using other regulatory procedures. Pharmacists indicated that the most
desired solutions which would support the PT development in Poland are a nation-
wide information campaign concerning PT and training for pharmacists on the
legal and economic aspects. The survey among consumers revealed that 90% of
respondents had not ever heard about PT. 51% of consumers indicated that lower
price is the most important factor in convincing them to purchase PT medicines.
CONCLUSIONS: Pharmacists have limited knowledge about PT. There is a strong
need for training directed at pharmacists. The hospital market is still under-ex-
plored in Poland and therefore represents a very attractive opportunity for the PT
development. Only 10% of consumers are familiar with the PT concept which re-
veals the urgent need for a nationwide campaign to highlight the issue of PT.
Product price is the most important incentive for consumers that in convincing
them to purchase PT products.
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OBJECTIVES:An extensive insight into drug utilization as an economic and a public
health issue can only be obtained when related to the integrated health state of the
respective population.Our target is to investigate the utilization trends of cardio-
vascular drugs in Croatia during the period 2007- 2010, thus focusing on the most
common pharmacological/therapeutic subgroups. This allows us to make direct
comparisons with the number of patient’s hospital admissions connected to car-
diovascular events. METHODS: The data of drug utilization in Croatia is collected
and analyzed by the Croatian Agency for Medicinal Products and Medical Devices
HALMED. By applying the Anatomical-Therapeutic-Chemical methodology (ATC),
the given data is used to calculate the number of defined daily doses (DDD) and
DDD per 1000 inhabitants per day (DDD/1000/day) between 2007-2010, whereas the
data of hospital statistics is analyzed by The Public Health Institute. RESULTS: The
utilization of all cardiovascular drugs indicate an increase of 47.55% (from 248.88
DDD/1000/day in 2007 to 367.23 DDD/1000/day in 2010), while the total cost in-
creased for 13.09% (from 863,601,721 KN in 2007 to 976,657,904 KN in 2010). The
utilization of the lipid modifying agents (C10) increased the most (78.93%), followed
by agents acting on the renin-angiotensin system (57.51%) and succeeded by cal-
cium channel blockers (28.46%). The total number of hospital admissions related to
cardiovascular diseases decreased from 84,413 in 2007 to 81,575 in 2010.
CONCLUSIONS:During the period 2007-2010 the utilization of cardiovascular drugs
increased significantly. In the same period the number of hospital admissions of
the patients with main cardiovascular events (3.4%) indicated a decrease. It is
necessary to undertake further analysis of these co-founders.
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OBJECTIVES: In Malaysia public sector, medicines spending in Ministry of Health
health facilities has increased by 428% from 1998 to 2008. The ultimate aim of this
research is to examine the trend of medicine expenditure and to identify the fac-
tors associated with the changes in medicine expenditure. METHODS: This was a
cross-sectional study. It studied prescriptions from 2007 to 2009 at the Pharmacy
Department of SFMS Hospital in Johor State. Simple linear regression and multiple
linear regression analysis were conducted. RESULTS: Total medicines expendi-
tures for outpatient and inpatient rose every year. In outpatient, volume of medi-
cine utilization increased over the years. Medicine expenditure declined in 2009
despite the continuous rise of medicines utilization. Median cost per medicine
declined throughout these three years. Inpatient had a continuous rise in medicine
expenditure. Median cost per medicine was fluctuating between 2007 and 2009 and
was about 35% lower than outpatient. In outpatient, median cost per medicine was
significantly different between years 2007, 2008 and 2009 for all variables except for
hospital discipline Paediatric and X-ray. Meanwhile in inpatient, the exception was
for Dermatology, X-ray, Ophthalmology and Dental. The study found that volume
of medicine utilization, which includes the number of medicines, number of med-
icines per prescription and duration of supply, contributed significantly to the
increase of medicine expenditure. Demographics, price and new medicine ap-
proved in the formulary were found to have no impact. CONCLUSIONS: The in-
crease of medicine utilization rate could be due to the increase of population; the
increase of the elderly population and new treatment guidelines and treatment
which was previously not available. Other factors include off-label prescribing,
irrational prescribing and poly-pharmacy. These three factors can lead to medica-
tion wastage and higher cost of treatment. Duration of medicine supply must be
carefully monitored as longer duration might result in medication wastage.
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OBJECTIVES: The signing of the TRIPS agreement in 1995 and Doha Declaration in
2001 have allowed low and middle-income countries to issue compulsory licenses
(CLs) for medicines in times of national emergency. While normally for infectious
diseases, given the epidemiologic transition occurring in these countries along
with the development of insurance systems, it is likely that the trend in the next
decade will be towards a higher demand for more expensive medicines to treat
non-communicable diseases (NCDs). We sought to determine the impact of CLs for
medicines that treat NCDs and make recommendations as to how pharmaceutical
companies and governments can work together in the future. METHODS: We ana-
lysed a series of cases where a CL was issued, or the manufacturer successfully
negotiated to retain patent rights for drugs treating NCDs to determine the relative
impact of the CL or negotiations, prices were benchmarked and compared before
and after CL issuance in 2012 US dollars using the medical commodities consumer
price index and relevant exchange rates. RESULTS: Of nine CL cases identified, six
resulted in an issued license, two were withdrawn, and one was negotiated and
resulted in a discount and cost sharing agreement. For licenses issued, the average
price reduction was 86.2% and supply was issued to a generics manufacturer.
Roche recently decreased the prices of three of its products by an average of 91.0%
in India - indicating there may be a trend to reducing price in order to protect patent
rights and avoid CL issuance. CONCLUSIONS: Low-income countries are increas-
ingly using CLs to obtain lower prices for medicines to treat NCDs. Price negotiation
tended to result in a greater price decrease than issued CLs, highlighting the im-
portance placed on retaining patent rights. Pharma companies could consider pro-
actively seeking cost-sharing arrangements to provide access to low-income pa-
tients and maintain market exclusivity.
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OBJECTIVES: To investigate the horizontal equity concerning the use of primary
health care services in Greece in 2006 and in 2011. Given that the economic crisis
affects the health care system in Greece, the comparison between the findings
depicts the post-crisis effects on the use of primary health care services.
METHODS: The research is based on two cross-sectional surveys, which took place
in 2006 and in 2011, and the sample size was 4003 and 6569 respectively. Moreover,
a random, stratified sampling was applied in both cases, which took into account
the age, the gender, the urbanization rate and the geographical region. RESULTS:
The Concentration Index for the measurement of horizontal equity (CHE) can be
estimated as CU-CN. The CU index depicts the use of primary health care services,
based on the number of medical visits. Additionally, the CN index intends to specify
the use of primary health care services in terms of need for care. It is also notewor-
thy that CN was estimated after applying the Poisson Regression method (depen-
dent variable: use of primary health care services, independent variables: self as-
sessed health status and chronic health problems). According to the results, CHE
was 0.06 in 2006, as CU and CN were estimated at 0.14 and 0.08 respectively.
Furthermore, CU was0.06, while CN was estimated at0.04 in 2011. Therefore CHE
decreased to 0.02. CONCLUSIONS: The low-income individuals tend to use pri-
mary health care services more than the high-income individuals, regardless the
economic crisis. This finding can be explained, as the low income is usually accom-
panied with a lower health status. Generally, as CHE is close to zero, there are not
strong indications of inequality. However, CHE increased in 2011 (closer to zero),
which implies that the inequality shifted from higher income individuals.
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OBJECTIVES: Cancer drugs are the world’s highest selling category of therapeutic
products. Due to their premium price and budget impact, several new drug reim-
bursement models have been implemented worldwide by public and private pay-
ers. These models have potential implications for coverage and reimbursement of
all branded products. This study reviewed recent cancer drug reimbursement mod-
els and developed lessons and implications for future products. METHODS: Re-
viewed cancer drug reimbursement schemes in developed and emerging markets.
Interviewed payers and KOLs to develop lessons and implications for future
products. RESULTS: Public and private payers worldwide have implemented sev-
eral new models for cancer drug reimbursement to manage budgets and control
costs. In the US, private payers are piloting single source compendia and third party
protocols (eg. P4 Oncology) to limit off-label use of cancer drugs. In the UK, NICE has
successfully negotiated lower price and discounts for first few cycles of therapy. In
Italy, AIFA has implemented registry based patient access for cancer drugs. In
India, several manufacturers have implemented novel pricing strategy for first few
cycles of therapy. In Germany, IQWIG has proposed to use correlations between
surrogate endpoints and patient relevant outcomes to determine value of cancer
drugs. Due to increased cost pressure on payers, such models are likely to inspire
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